The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Sep 2013
Randomized Controlled TrialDose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
Asthma is a disease with marked heterogeneity in its clinical course and response to treatment. IL-13 is central to type 2 inflammation, which contributes to many key features of asthma. Lebrikizumab is an anti-IL-13 mAb previously reported to significantly improve lung function in patients with inadequately controlled asthma despite inhaled corticosteroid therapy, especially in periostin-high patients. ⋯ Blocking IL-13, a single cytokine, in this population of asthmatic patients is insufficient to improve lung function. There is evidence that IL-13 blockade may improve disease control, as measured by prevention of protocol-defined treatment failure in these patients.
-
J. Allergy Clin. Immunol. · Sep 2013
Novel immunologic classification of aspergillosis in adult cystic fibrosis.
Patients with cystic fibrosis (CF) demonstrate a wide range of hypersensitivity responses to Aspergillus, beyond allergic bronchopulmonary aspergillosis, which require classification. ⋯ Three distinct classes of aspergillosis in CF were identified by latent class analysis by using serologic, RT-PCR, and GM data. This novel classification will facilitate improved phenotyping, pathogenesis studies, and management evaluations.
-
J. Allergy Clin. Immunol. · Sep 2013
Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing.
Previous studies have suggested the presence of different childhood wheeze phenotypes through statistical modeling based on parentally reported wheezing. ⋯ We identified a novel group of children with persistent troublesome wheezing, who have markedly different outcomes compared with persistent wheezers with controlled disease.